A326030 Stock Overview
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A326030 from our risk checks.
SK Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩97,500.00 |
| 52 Week High | ₩130,000.00 |
| 52 Week Low | ₩72,600.00 |
| Beta | 0.91 |
| 11 Month Change | -20.86% |
| 3 Month Change | -8.88% |
| 1 Year Change | 10.05% |
| 33 Year Change | -2.21% |
| 5 Year Change | n/a |
| Change since IPO | -23.23% |
Recent News & Updates
There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22Recent updates
There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn
Mar 12Shareholder Returns
| A326030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -10.6% | -9.2% | -2.8% |
| 1Y | 10.0% | 8.0% | -3.4% |
Return vs Industry: A326030 exceeded the KR Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: A326030 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A326030 volatility | |
|---|---|
| A326030 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A326030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A326030's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 241 | Dong Hoon Lee | www.skbp.com |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.
SK Biopharmaceuticals Co., Ltd. Fundamentals Summary
| A326030 fundamental statistics | |
|---|---|
| Market cap | ₩7.64t |
| Earnings (TTM) | ₩33.80b |
| Revenue (TTM) | ₩465.06b |
225.9x
P/E Ratio16.4x
P/S RatioIs A326030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A326030 income statement (TTM) | |
|---|---|
| Revenue | ₩465.06b |
| Cost of Revenue | ₩41.46b |
| Gross Profit | ₩423.60b |
| Other Expenses | ₩389.81b |
| Earnings | ₩33.80b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 431.55 |
| Gross Margin | 91.08% |
| Net Profit Margin | 7.27% |
| Debt/Equity Ratio | 46.5% |
How did A326030 perform over the long term?
See historical performance and comparison